Another Phase III Study Supports Avastin Expansion To Ovarian Cancer
This article was originally published in Pharmaceutical Approvals Monthly
Roche/Genentech's Avastin took another step toward an indication in ovarian cancer with the July 2 release of positive top-line results from a second Phase III study showing a benefit in progression-free survival
You may also be interested in...
The U.K.'s health care cost regulator says it wouldn't recommend Roche's Avastin as a first-line treatment for advanced ovarian cancer along with standard chemotherapy, on grounds it doesn’t offer value for money.
Roche's Long View: ASCO Marks Progress In Shifting To Lengthier Treatment Duration For Avastin, Rituxan
CHICAGO - Roche's current focus in oncology is on establishing longer treatment durations for its oncologics, including its mega-blockbuster Avastin (bevacizumab)
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011